• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > News

2024 R&D programmes in review: Pandemic preparedness

Home > News

2024 R&D programmes in review: Pandemic preparedness

Lab activities
4 Mar 2025

DNDi and our partners are working to accelerate research to prepare for future viral pandemics. Utilizing our experience in non-profit drug development and partnerships with medical research institutions worldwide, our drug discovery teams are focused on identifying new broad-spectrum antivirals targeting several families of viruses recognized by WHO as presenting the greatest epidemic and pandemic potential in humans. Employing open science, AI, and cutting-edge research tools, our goal is to advance new drug candidates through Phase I safety trials to have them ready for testing against emerging viruses with pandemic potential. 

Our progress in 2024 includes:

Icon of a microscope

Discovery

Nucleoside Booster: All 23 nucleosides selected for primary screening (four with broad-spectrum antiviral activity and 19 with more restricted specific antiviral activity, based on primary screening data) have been resupplied to the six DZIF-affiliated screening centres for dose-response measurements against 10 viral diseases using 17 distinct viral assay systems. Parallel testing for cytotoxicity of these 23 compounds was also undertaken in seven cell lines. Analysis of all acquired data identified four promising candidates associated with broad-spectrum antiviral activity in the viral assays.

TMEM16 series: New salicylamide derivatives with improved physiochemical profiles have been designed and synthesized, confirming that it is feasible to significantly improve the drug property profiles of compounds in the series. Work is now focused on improving the antiviral potency of the compounds in the sub-series and confirming a favourable plasma exposure profile before assessing in vivo antiviral efficacy.

COVID Moonshot: The Moonshot backup compound, ASAP-0017445, has now progressed to a stage that allows for exploratory dose-range-finding or maximum-tolerated-dose studies with sufficient amounts of material synthesized to support these studies (>400 g). Extensive in vitro pre-clinical profiling indicates a very promising profile, in addition ASAP-0017445 show in vitro and in vivo efficacy against a panel of human and non-human coronaviruses. Pharmacokinetic characterization across multiple species and a promising preliminary human dose prediction further support progression of this compound.

AViDD ASAP: The project continued its focus on the discovery and development of novel antiviral drugs targeting three viral families: flaviviruses, coronaviruses, and enteroviruses. The leading programme targeting MERS/SARS-CoV-2 MPro inhibitors selected a shortlist of compounds that confirms MERS-CoV activity in pre-clinical infection models. These compounds are now being progressed towards pre-clinical toxicology studies. A second programme focused on the discovery of dengue and Zika virus NS2B-NS3 protease inhibitors has now entered the lead-optimization phase with the aim of developing a compound with confirmed in vivo efficacy.

Icon of 5 people

Development

ANTICOV: A total of 1,942 patients were randomized in 12 countries prior to the study’s conclusion. Database lock was completed in November 2023, and data were transferred to the Infectious Diseases Data Observatory (IDDO) platform to ensure worldwide accessibility to other researchers. Final results were available in December 2023. The clinical study report was completed in March 2024.

ANTICOV was completed in 2024, with five treatments tested. Early futility was demonstrated for one arm, but due to the low probability of reaching any statistical significance after the Omicron wave, it was decided to stop the study.

Photo credit: Yaw Afrim Gyebi-DNDi

Clinical trials Drug discovery Pandemic Preparedness

Read, watch, share

Loading...
News
6 Jun 2025

DNDi is partnering with Médecins Sans Frontières South Asia for the Without Borders Media Fellowship 2025 

News
5 Jun 2025

Meet the DNDi Eastern Africa 2024-2025 Media Fellows

Press releases
5 Jun 2025

Colombia becomes first country to recommend rapid tests to diagnose Chagas disease

Statements
27 May 2025

DNDi interventions at the 78th World Health Assembly

Press releases
22 May 2025

Six African nations commit to eliminate deadly neglected disease visceral leishmaniasis

Videos
20 May 2025

The Children of the Sierra

Press releases
13 May 2025

First all-oral treatment for a rare but deadly strain of sleeping sickness now available and being used to treat patients in endemic countries in Africa

Statements
8 May 2025

DNDi’s briefing note for 78th World Health Assembly

VIEW ALL

Help neglected patients

To date, we have delivered thirteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License